These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26161927)

  • 1. KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma.
    Bittoni A; Piva F; Santoni M; Andrikou K; Conti A; Loretelli C; Mandolesi A; Lanese A; Pellei C; Scarpelli M; Principato G; Cascinu S
    Future Oncol; 2015; 11(13):1905-17. PubMed ID: 26161927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS in pancreatic cancer.
    Agarwal A; Saif MW
    JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated With Smaller Lesions.
    Nagawkar SS; Abu-Funni S; Simon E; Bick T; Prinz E; Sabo E; Ben-Izhak O; Hershkovitz D
    Pancreas; 2016 Jul; 45(6):876-81. PubMed ID: 26646269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
    Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
    Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survivors of pancreatic adenocarcinoma show low rates of genetic alterations in KRAS, TP53 and SMAD4.
    Masetti M; Acquaviva G; Visani M; Tallini G; Fornelli A; Ragazzi M; Vasuri F; Grifoni D; Di Giacomo S; Fiorino S; Lombardi R; Tuminati D; Ravaioli M; Fabbri C; Bacchi-Reggiani ML; Pession A; Jovine E; de Biase D
    Cancer Biomark; 2018 Feb; 21(2):323-334. PubMed ID: 29103024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium.
    Lüttges J; Schlehe B; Menke MA; Vogel I; Henne-Bruns D; Klöppel G
    Cancer; 1999 Apr; 85(8):1703-10. PubMed ID: 10223563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer.
    Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.
    Hashimoto D; Arima K; Yokoyama N; Chikamoto A; Taki K; Inoue R; Kaida T; Higashi T; Nitta H; Ohmuraya M; Hirota M; Beppu T; Baba H
    Pancreas; 2016 Sep; 45(8):1111-4. PubMed ID: 26967456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the Long Noncoding RNA HomeoboxA Transcript at the Distal Tip Predicts Poor Prognosis in a KRAS-Independent Manner in Periampullary Region Tumors.
    Balcin O; Ak Aksoy S; Tunca B; Kaya E; Egeli U; Tezcan G; Ugras N; Cecener G; Isik O; Dundar HZ; Yerci O
    Pancreas; 2018 Feb; 47(2):213-220. PubMed ID: 29329159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
    Falk AT; Yazbeck N; Guibert N; Chamorey E; Paquet A; Ribeyre L; Bence C; Zahaf K; Leroy S; Marquette CH; Cohen C; Mograbi B; Mazières J; Hofman V; Brest P; Hofman P; Ilié M
    Lung Cancer; 2018 Jul; 121():70-75. PubMed ID: 29858030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review.
    Kim BJ; Jang HJ; Kim JH; Kim HS; Lee J
    Oncotarget; 2016 Sep; 7(36):58001-58006. PubMed ID: 27517148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
    Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In pancreatic ductal adenocarcinoma blood concentrations of some organochlorine compounds and coffee intake are independently associated with KRAS mutations.
    Porta M; López T; Pumarega J; Jariod M; Crous-Bou M; Marco E; Rifà J; Grimalt JO; Malats N; Real FX;
    Mutagenesis; 2009 Nov; 24(6):513-21. PubMed ID: 19797353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical study of genetic alterations in intraductal and invasive ductal tumors of the pancreas.
    Islam HK; Fujioka Y; Tomidokoro T; Sugiura H; Takahashi T; Kondo S; Katoh H
    Hepatogastroenterology; 2001; 48(39):879-83. PubMed ID: 11462947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic carcinosarcoma with the same KRAS gene mutation in both carcinomatous and sarcomatous components: molecular evidence for monoclonal origin of the tumour.
    Bai Q; Zhang X; Zhu X; Wang L; Huang D; Cai X; Zhou X; Wang J; Sheng W
    Histopathology; 2016 Sep; 69(3):393-405. PubMed ID: 27307095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
    Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
    Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five primary human pancreatic adenocarcinoma cell lines established by the outgrowth method.
    Rückert F; Aust D; Böhme I; Werner K; Brandt A; Diamandis EP; Krautz C; Hering S; Saeger HD; Grützmann R; Pilarsky C
    J Surg Res; 2012 Jan; 172(1):29-39. PubMed ID: 21683373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation.
    Yang D; Sun X; Moniruzzaman R; Wang H; Citu C; Zhao Z; Wistuba II; Wang H; Maitra A; Chen Y
    Cell Rep Med; 2024 Sep; 5(9):101711. PubMed ID: 39232498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.